Arizona State Retirement System Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Arizona State Retirement System raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,562 shares of the biopharmaceutical company’s stock after buying an additional 1,028 shares during the period. Arizona State Retirement System’s holdings in Catalyst Pharmaceuticals were worth $513,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Catalyst Pharmaceuticals by 119.6% in the third quarter. BlackRock Inc. now owns 15,268,931 shares of the biopharmaceutical company’s stock valued at $195,902,000 after buying an additional 8,317,115 shares in the last quarter. State Street Corp grew its position in shares of Catalyst Pharmaceuticals by 39.0% in the third quarter. State Street Corp now owns 7,555,423 shares of the biopharmaceutical company’s stock valued at $96,936,000 after purchasing an additional 2,117,944 shares during the period. Vanguard Group Inc. grew its position in shares of Catalyst Pharmaceuticals by 26.3% in the third quarter. Vanguard Group Inc. now owns 6,139,650 shares of the biopharmaceutical company’s stock valued at $78,772,000 after purchasing an additional 1,277,662 shares during the period. Millennium Management LLC grew its position in shares of Catalyst Pharmaceuticals by 134.1% in the second quarter. Millennium Management LLC now owns 2,723,895 shares of the biopharmaceutical company’s stock valued at $19,095,000 after purchasing an additional 1,560,086 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Catalyst Pharmaceuticals by 115.8% in the third quarter. Renaissance Technologies LLC now owns 2,226,512 shares of the biopharmaceutical company’s stock valued at $28,566,000 after purchasing an additional 1,194,900 shares during the period. Hedge funds and other institutional investors own 86.66% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CPRX shares. Cantor Fitzgerald lifted their target price on shares of Catalyst Pharmaceuticals from $22.00 to $25.00 in a research report on Friday, March 17th. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, May 15th. Finally, Piper Sandler lifted their target price on shares of Catalyst Pharmaceuticals from $20.00 to $21.00 in a research report on Tuesday, February 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $21.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $16.83, for a total value of $504,900.00. Following the transaction, the director now directly owns 313,541 shares in the company, valued at approximately $5,276,895.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $16.83, for a total value of $504,900.00. Following the transaction, the director now directly owns 313,541 shares in the company, valued at approximately $5,276,895.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Patrick J. Mcenany sold 26,151 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $13.23, for a total transaction of $345,977.73. Following the completion of the transaction, the chief executive officer now owns 3,945,436 shares in the company, valued at $52,198,118.28. The disclosure for this sale can be found here. Insiders have sold 246,151 shares of company stock worth $3,974,706 in the last ninety days. 14.10% of the stock is owned by insiders.

Catalyst Pharmaceuticals Trading Down 0.2 %

CPRX opened at $12.17 on Friday. The firm has a market capitalization of $1.29 billion, a PE ratio of 13.83 and a beta of 1.11. Catalyst Pharmaceuticals, Inc. has a twelve month low of $6.15 and a twelve month high of $22.11. The firm’s 50-day moving average price is $16.11 and its 200 day moving average price is $16.49.

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) last posted its quarterly earnings results on Wednesday, March 15th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. The firm had revenue of $60.76 million for the quarter, compared to analyst estimates of $60.64 million. Catalyst Pharmaceuticals had a net margin of 38.76% and a return on equity of 34.72%. As a group, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.17 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.